NGS Protocol IDs Actionable Mutations in Pediatric Cancer Cases but Significant Challenges Remain | GenomeWeb

NEW YORK (GenomeWeb) – University of Michigan researchers have found that for pediatric cancer patients, a comprehensive sequencing protocol was able to identify an actionable mutation in about 46 percent of patients and led to a clinical action in 54 percent of the group. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.